Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia

Matyas Meggyes, Eva Miko, Adrienn Lajko, Beata Csiszar, Barbara Sandor, Peter Matrai, Peter Tamas, L. Szereday

Research output: Contribution to journalArticle

Abstract

The programmed cell death protein 1 (PD-1) receptor has been reported to downregulate T cell activation effectively via binding to its ligands PD-L1 or PD-L2 in a negative co-stimulatory manner. Little is known about the involvement of PD-1 mediated immunoregulation in pregnancy and in pregnancy-related disorders. In this work, we investigated the possible role of the PD-1 co-stimulatory pathway in the pathogenesis of the clinical phase of early-onset preeclampsia characterized by a systemic maternal inflammatory response. We performed a cross-sectional study for comparative analysis of phenotypic and functional characteristics of peripheral blood mononuclear cells in women with early-onset preeclampsia and third-trimester healthy pregnant controls. According to our findings, enhanced expression of either PD-1 or its ligand PD-L1, or both, on the cell surface of effector cells (T cells, natural killer (NK) cells, natural killer T (NKT)-like cells) and Tregs could be observed, but PD-1 expression did not correlate with effector cells exhaustion. These results suggest the failure of the axis to downregulate Th1 responses, contributing thereby to the exaggerated immunoactivation observed in early-onset preeclampsia.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume20
Issue number3
DOIs
Publication statusPublished - Jan 29 2019

Fingerprint

Programmed Cell Death 1 Receptor
pathogenesis
T-cells
Pre-Eclampsia
Ligands
effectors
Cell death
Down-Regulation
cells
pregnancy
T-Lymphocytes
Pregnancy
Natural Killer T-Cells
Blood
Chemical activation
Third Pregnancy Trimester
Proteins
Natural Killer Cells
Blood Cells
exhaustion

Keywords

  • early-onset
  • immune checkpoint
  • inflammation
  • PD-1
  • PD-L1
  • preeclampsia

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia. / Meggyes, Matyas; Miko, Eva; Lajko, Adrienn; Csiszar, Beata; Sandor, Barbara; Matrai, Peter; Tamas, Peter; Szereday, L.

In: International Journal of Molecular Sciences, Vol. 20, No. 3, 29.01.2019.

Research output: Contribution to journalArticle

Meggyes, Matyas ; Miko, Eva ; Lajko, Adrienn ; Csiszar, Beata ; Sandor, Barbara ; Matrai, Peter ; Tamas, Peter ; Szereday, L. / Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia. In: International Journal of Molecular Sciences. 2019 ; Vol. 20, No. 3.
@article{67a85e545efa4700ac79b791beb21c02,
title = "Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia",
abstract = "The programmed cell death protein 1 (PD-1) receptor has been reported to downregulate T cell activation effectively via binding to its ligands PD-L1 or PD-L2 in a negative co-stimulatory manner. Little is known about the involvement of PD-1 mediated immunoregulation in pregnancy and in pregnancy-related disorders. In this work, we investigated the possible role of the PD-1 co-stimulatory pathway in the pathogenesis of the clinical phase of early-onset preeclampsia characterized by a systemic maternal inflammatory response. We performed a cross-sectional study for comparative analysis of phenotypic and functional characteristics of peripheral blood mononuclear cells in women with early-onset preeclampsia and third-trimester healthy pregnant controls. According to our findings, enhanced expression of either PD-1 or its ligand PD-L1, or both, on the cell surface of effector cells (T cells, natural killer (NK) cells, natural killer T (NKT)-like cells) and Tregs could be observed, but PD-1 expression did not correlate with effector cells exhaustion. These results suggest the failure of the axis to downregulate Th1 responses, contributing thereby to the exaggerated immunoactivation observed in early-onset preeclampsia.",
keywords = "early-onset, immune checkpoint, inflammation, PD-1, PD-L1, preeclampsia",
author = "Matyas Meggyes and Eva Miko and Adrienn Lajko and Beata Csiszar and Barbara Sandor and Peter Matrai and Peter Tamas and L. Szereday",
year = "2019",
month = "1",
day = "29",
doi = "10.3390/ijms20030583",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia

AU - Meggyes, Matyas

AU - Miko, Eva

AU - Lajko, Adrienn

AU - Csiszar, Beata

AU - Sandor, Barbara

AU - Matrai, Peter

AU - Tamas, Peter

AU - Szereday, L.

PY - 2019/1/29

Y1 - 2019/1/29

N2 - The programmed cell death protein 1 (PD-1) receptor has been reported to downregulate T cell activation effectively via binding to its ligands PD-L1 or PD-L2 in a negative co-stimulatory manner. Little is known about the involvement of PD-1 mediated immunoregulation in pregnancy and in pregnancy-related disorders. In this work, we investigated the possible role of the PD-1 co-stimulatory pathway in the pathogenesis of the clinical phase of early-onset preeclampsia characterized by a systemic maternal inflammatory response. We performed a cross-sectional study for comparative analysis of phenotypic and functional characteristics of peripheral blood mononuclear cells in women with early-onset preeclampsia and third-trimester healthy pregnant controls. According to our findings, enhanced expression of either PD-1 or its ligand PD-L1, or both, on the cell surface of effector cells (T cells, natural killer (NK) cells, natural killer T (NKT)-like cells) and Tregs could be observed, but PD-1 expression did not correlate with effector cells exhaustion. These results suggest the failure of the axis to downregulate Th1 responses, contributing thereby to the exaggerated immunoactivation observed in early-onset preeclampsia.

AB - The programmed cell death protein 1 (PD-1) receptor has been reported to downregulate T cell activation effectively via binding to its ligands PD-L1 or PD-L2 in a negative co-stimulatory manner. Little is known about the involvement of PD-1 mediated immunoregulation in pregnancy and in pregnancy-related disorders. In this work, we investigated the possible role of the PD-1 co-stimulatory pathway in the pathogenesis of the clinical phase of early-onset preeclampsia characterized by a systemic maternal inflammatory response. We performed a cross-sectional study for comparative analysis of phenotypic and functional characteristics of peripheral blood mononuclear cells in women with early-onset preeclampsia and third-trimester healthy pregnant controls. According to our findings, enhanced expression of either PD-1 or its ligand PD-L1, or both, on the cell surface of effector cells (T cells, natural killer (NK) cells, natural killer T (NKT)-like cells) and Tregs could be observed, but PD-1 expression did not correlate with effector cells exhaustion. These results suggest the failure of the axis to downregulate Th1 responses, contributing thereby to the exaggerated immunoactivation observed in early-onset preeclampsia.

KW - early-onset

KW - immune checkpoint

KW - inflammation

KW - PD-1

KW - PD-L1

KW - preeclampsia

UR - http://www.scopus.com/inward/record.url?scp=85060920835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060920835&partnerID=8YFLogxK

U2 - 10.3390/ijms20030583

DO - 10.3390/ijms20030583

M3 - Article

C2 - 30700015

AN - SCOPUS:85060920835

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 3

ER -